CoChat

Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon

Open access
Jeon, Eonju, Lee, Ki Young, Kim, Kyoung-Kon · 2023 · Journal of Obesity & Metabolic Syndrome

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Obesity is a prevalent global health issue affecting approximately half of the world's population.Extensive scientific research highlights the urgent need for effective obesity management to mitigate health risks and prevent complications.While bariatric surgery has proven to be highly effective, providing substantial short-term and long-term weight loss and resolution of obesity-related comorbidities, it is important to recognize its limitations and associated risks.Given the global obesity epidemic and the limitations of surgical interventions, there is high demand for effective and safe anti-obesity medications (AOMs).In Korea, the Korean Society for the Study of Obesity strongly advocates for the use of pharmacotherapy in Korean adults with a body mass index of 25 kg/m² or higher who have not achieved weight reduction through non-pharmacological treatments.Currently, five AOMs have been approved for long-term weight management: orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, and semaglutide.Tirzepatide is awaiting approval, and compounds such as CagriSema (Novo Nordisk) and oral semaglutide are currently undergoing rigorous evaluation in phase 3 clinical trials.Furthermore, other promising drugs, including orforglipron, BI 456906, and retartrutide, are progressing to phase 3 studies, expanding the therapeutic options for obesity management.In personalized patient care, physicians play a crucial role in accurately identifying individuals who genuinely require pharmacotherapy and selecting appropriate AOMs based on individual patient characteristics.By integrating evidence-based interventions and considering the unique needs of patients, healthcare professionals significantly contribute to the success of obesity management strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7570/jomes23032

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The direct physiologic effects of endogenous glucagon-like peptide-1 (GLP-1; black arrows), glucose-dependent insulinotropic polypeptide (GIP; green arrows), glucagon (red arrows), and amylin (blue arrows). The corresponding representation of these four peptides in target tissues is denoted by a black asterisk, green triangle, red rectangle, and blue circle, respectively. These four peptides exert their effects on the hypothalamus, either directly or indirectly through neuronal conduction, ultimately leading to a reduction in food intake. Adapted from Kim.33 AP, area postrema; NTS, nucleaus tractus solitarius; BAT, brown adipose tissue; WAT, white adipose tissue.
Figure 1 The direct physiologic effects of endogenous glucagon-like peptide-1 (GLP-1; black arrows), glucose-dependent insulinotropic polypeptide (GIP; green arrows), glucagon (red arrows), and amylin (blue arrows). The corresponding representation of these four peptides in target tissues is denoted by a black asterisk, green triangle, red rectangle, and blue circle, respectively. These four peptides exert their effects on the hypothalamus, either directly or indirectly through neuronal conduction, ultimately leading to a reduction in food intake. Adapted from Kim.33 AP, area postrema; NTS, nucleaus tractus solitarius; BAT, brown adipose tissue; WAT, white adipose tissue.CC BY-NC · PubMed Central
Figure 2 The recommended dosing schedule for liraglutide, semaglutide, and tirzepatide. Short arrows indicate a single dose, while long arrows represent daily administration. This dosing schedule reflects the recommended escalation and maintenance method outlined in the product manual. The recommended escalation method is to increase liraglutide by 0.6 mg every week until a maximum of 3.0 mg, increase semaglutide subcutaneous injection by 0.25–0.5–1.0–1.7–2.4 mg every 4 weeks, increase oral semaglutide by 3–7–14–25–50 mg every 4 weeks, and increase tirzepatide by 2.5 mg every 4 weeks until a maximum of 15 mg. However, it is important to individualize the escalation rate, maintenance dosage, and other factors based on the individual’s response to treatment.
Figure 2 The recommended dosing schedule for liraglutide, semaglutide, and tirzepatide. Short arrows indicate a single dose, while long arrows represent daily administration. This dosing schedule reflects the recommended escalation and maintenance method outlined in the product manual. The recommended escalation method is to increase liraglutide by 0.6 mg every week until a maximum of 3.0 mg, increase semaglutide subcutaneous injection by 0.25–0.5–1.0–1.7–2.4 mg every 4 weeks, increase oral semaglutide by 3–7–14–25–50 mg every 4 weeks, and increase tirzepatide by 2.5 mg every 4 weeks until a maximum of 15 mg. However, it is important to individualize the escalation rate, maintenance dosage, and other factors based on the individual’s response to treatment.CC BY-NC · PubMed Central
Figure 3 The percentage of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% weight loss for each medication. Data were extracted from the following trials: XENical in the Prevention of Diabetes in Obese Subjects (XENDOS; orlistat),8 Contrave Obesity Research I (COR-I; naltrexone/bupropion [NB] extended-release [ER]),23 Satiety and Clinical Adiposity-Liraglutide (SCALE) Obesity and Prediabetes and its extension (liraglutide 3.0 mg),37,40 EQUIP (phentermine/topiramate [P/T] ER 1 year),49 SEQUEL (P/T ER 2 years),31 Semaglutide Treatment Effect in People with obesity (STEP) 1 (semaglutide 2.4 mg),13 and SURMOUNT-1 (tirzepatide 15 mg).48
Figure 3 The percentage of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% weight loss for each medication. Data were extracted from the following trials: XENical in the Prevention of Diabetes in Obese Subjects (XENDOS; orlistat),8 Contrave Obesity Research I (COR-I; naltrexone/bupropion [NB] extended-release [ER]),23 Satiety and Clinical Adiposity-Liraglutide (SCALE) Obesity and Prediabetes and its extension (liraglutide 3.0 mg),37,40 EQUIP (phentermine/topiramate [P/T] ER 1 year),49 SEQUEL (P/T ER 2 years),31 Semaglutide Treatment Effect in People with obesity (STEP) 1 (semaglutide 2.4 mg),13 and SURMOUNT-1 (tirzepatide 15 mg).48CC BY-NC · PubMed Central
Figure 4 The manner of action on the glucagon-like peptide-1 (GLP-1) receptor differs between native GLP-1 and LY3502970 (orforglipron). The GLP-1 receptor belongs to the class B G-protein coupled receptor (GPCR) family. Schematic explanations A to D illustrate the classic model of G-protein-mediated activation and β-arrestin-related desensitization in GLP-1 receptor agonism by native GLP-1, while E demonstrates the biased agonism of LY3502970 on the GLP-1 receptor. (A) Inactive state of the GLP-1 receptor. (B) Activated GLP-1 receptor with attached GLP-1, leading to the substitution of guanosine diphosphate (GDP) with guanosine triphosphate (GTP) on the α subunit of the Gs protein (Gαs). (C) Gα dissociates from the G-protein and stimulates adenyl cyclase (AC), converting adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) and resulting in elevated cAMP levels. Simultaneously, the C-terminal tail of the GLP-1 receptor is phosphorylated by G protein-coupled receptor kinase (GRK), allowing β-arrestin to bind to the GLP-1 receptor, forming a complex. (D) Internalization of the GLP-1 receptor by β-arrestin. (E) The biased agonism of LY3502970 primarily proceeds through the cAMP pathway with reduced β-arrestin recruitment.58 This biased agonism is also exhibited by TT-OAD2, another orally administered nonpeptidic GLP-1R agonist compound.59 However, it is important to note that GPCR signaling is significantly more complex. GPCRs can couple with various G-protein families, activate them differentially depending on conditions, and also engage non-G-protein-related signaling pathways.60
Figure 4 The manner of action on the glucagon-like peptide-1 (GLP-1) receptor differs between native GLP-1 and LY3502970 (orforglipron). The GLP-1 receptor belongs to the class B G-protein coupled receptor (GPCR) family. Schematic explanations A to D illustrate the classic model of G-protein-mediated activation and β-arrestin-related desensitization in GLP-1 receptor agonism by native GLP-1, while E demonstrates the biased agonism of LY3502970 on the GLP-1 receptor. (A) Inactive state of the GLP-1 receptor. (B) Activated GLP-1 receptor with attached GLP-1, leading to the substitution of guanosine diphosphate (GDP) with guanosine triphosphate (GTP) on the α subunit of the Gs protein (Gαs). (C) Gα dissociates from the G-protein and stimulates adenyl cyclase (AC), converting adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) and resulting in elevated cAMP levels. Simultaneously, the C-terminal tail of the GLP-1 receptor is phosphorylated by G protein-coupled receptor kinase (GRK), allowing β-arrestin to bind to the GLP-1 receptor, forming a complex. (D) Internalization of the GLP-1 receptor by β-arrestin. (E) The biased agonism of LY3502970 primarily proceeds through the cAMP pathway with reduced β-arrestin recruitment.58 This biased agonism is also exhibited by TT-OAD2, another orally administered nonpeptidic GLP-1R agonist compound.59 However, it is important to note that GPCR signaling is significantly more complex. GPCRs can couple with various G-protein families, activate them differentially depending on conditions, and also engage non-G-protein-related signaling pathways.60CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

6 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Research works printed but not linked: 1

  1. Kim KK. Peptides in obesity treatment. Arch Obes Metab 2022;1:4-13.

Cited by

See all 39

Metadata

Authors
Jeon, E., Lee, K. Y., & Kim, K.-K.
Affiliations
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Daegu Catholic University School of Medicine, Daegu, Korea
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University College of Medicine, Incheon, Korea
  • Gachon University (KR)
Corresponding author
Kim, Kyoung-Kon
Venue
Journal of Obesity & Metabolic Syndrome
Published
2023-06-23
Volume
32
Issue
2
Pages
106-120
ISSN
  • 2508-6235 (ISSN-L)
  • 2508-7576
OpenAlex
W4381610885
Cited by
39
References
69
Citations by year
2026: 6 · 2025: 14 · 2024: 14 · 2023: 5
FWCI
1.42
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by-nc/4.0/ (tdm)
Locations
  • Journal of Obesity & Metabolic Syndrome (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
Keywords
anti-obesity drugs, obesity pharmacotherapy, orlistat, naltrexone/bupropion, phentermine/topiramate, liraglutide, semaglutide, tirzepatide, orforglipron, obesity treatment, drug approval

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. https://app.cochat.ai/papers/10.7570/jomes23032
The paper
Jeon, E., Lee, K. Y., & Kim, K.-K. (2023). Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon. Journal of Obesity & Metabolic Syndrome. https://doi.org/10.7570/jomes23032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.